Advertisement
Advertisement
Rybrevant

Rybrevant

amivantamab

Manufacturer:

Cilag
Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.
Core Prescribing Info
Contents
Amivantamab
Indications/Uses
Monotherapy for adult patients w/ locally advanced or metastatic NSCLC w/ activating epidermal-growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. In combination w/ carboplatin & pemetrexed for the 1st-line treatment of adult patients w/ locally advanced or metastatic NSCLC w/ activating EGFR exon 20 insertion mutations.
Dosage/Direction for Use
IV Administer infusion via peripheral line on wk 1 & 2 to minimize infusion-related reaction, & via central line for subsequent wk. Premed: Diphenhydramine 25-50 mg or equiv orally 30-60 min prior to infusion, or as IV 15-30 min prior to infusion. Acetaminophen 650-1,000 mg orally 30-60 min prior to infusion, or as IV 15-30 min prior to infusion. Dexamethasone 20 mg or equiv as IV 60-120 min prior to infusion, & 10 mg or equiv as IV 45-60 min prior to infusion. Administer at initial dose (wk 1, days 1 & 2) & optional for subsequent doses. Monotherapy in 3-wk dosing schedule Adult (≥18 yr) weighing ≥80 kg 1,750 mg (5 vials), followed by 2,100 mg (6 vials) every 3 wk starting at wk 7 onwards, <80 kg 1,400 mg (4 vials) followed by 1,750 mg (5 vials) every 3 wk starting at wk 7 onwards. Dosing schedule: Wk 1-4: Wkly (total of 4 doses): Wk 1: Split infusion on days 1 & 2; wk 2-4: Infusion on day 1. Monotherapy in 2-wk dosing schedule Adult (≥18 yr) weighing ≥80 kg 1,400 mg (4 vials), <80 kg 1,050 mg (3 vials). Dosing schedule: Wk 1-4: Wkly (total of 4 doses): Wk 1: Split infusion on days 1 & 2; wk 2-4: Infusion on day 1. Wk 5 onwards: Every 2 wk starting at wk 5. Combination w/ carboplatin & pemetrexed Administer in the following order: Pemetrexed 500 mg/m2 every 3 wk until disease progression or unacceptable toxicity. Carboplatin AUC 5 every 3 wk for up to 12 wk. Rybrevant every 3 wk (follow 3-wk dosing schedule), continue until disease progression or unacceptable toxicity.
Contraindications
Hypersensitivity.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01FX18 - amivantamab ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.
Presentation/Packing
Form
Rybrevant conc for soln for infusion 350 mg/7 mL
Packing/Price
1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement